Mass corporate software upgrade with virtually no disruption to daily workflow.


A multinational pharmaceutical and biopharmaceutical company with a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation.

Challenges:

A multinational pharmaceutical and biopharmaceutical company was under a firm deadline to have ALM upgraded from 11.52 to 12.55, eApprove replaced with VERA 2.3 and approximately 60 projects upgraded with as little disruption as possible to the user community.

Resolution:

Solution Components:


VERA version 2.3 was implemented, as well as upgrading approximately 60 projects from ALM 11.52 to ALM 12.55